|
|
| |
Drugs and Therapeutics (D & T) CommitteeDrugs Under Review for:June 25, 2008 |
| Drug Name |
Review Type |
Class |
Manufacturer |
| Duac CS |
New Drug Initial Review |
Topical Acne Agent |
Stiefel Labs |
| Evoclin Foam |
New Drug Initial Review |
Topical Acne Agent |
Stiefel Labs |
| Glumetza |
New Drug Initial Review |
Oral Anti-Hyperglycemic |
Depomed |
| Cimzia |
New Drug Initial Review |
Biologic Response Modifier |
UCB Pharma |
| Pristiq |
New Drug Initial Review |
SNRI Antidepressant |
Wyeth |
| Treximet |
New Drug Initial Review |
Triptans – Combination |
GlaxoSmithKline |
| Bystolic |
New Drug Initial Review |
Beta-Blocker |
Forest |
| Luvox CR |
New Drug Initial Review |
SSRI Antidepressant |
Jazz Pharmaceuticals |
| Voltaren Gel |
New Drug Initial Review |
Topical NSAID |
Endo |
| Iquix |
New Drug Appeal |
Ophthalmic Anti-infective |
Vistakon Pharmaceuticals, LLC |
| Sanctura XR |
New Drug Appeal |
Urinary-Anti-Incontinence |
Allergan |
| Vyvanse |
New Drug Appeal |
Stimulant/ADHD Agent |
Shire US, Inc. |
| Combigan |
New Drug Appeal |
Ophthalmics-Glaucoma |
Allergan |
| Vusion |
New Drug Appeal |
Topical Antifungal |
Barrier Therapeutics, Inc |
| Strattera |
PDL Appeal |
ADHD Agent |
Eli Lilly |
| Lovaza |
PDL Appeal |
Lipotropics – Other |
GlaxoSmithKline |
| Fazaclo |
PDL Appeal |
Atypical Antipsychotic |
Azur |
|
|
|
|
